Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, raised $39 million by offering 3.3 million shares at $12, within the range of $11 to $13. The company offered 0.8 million more shares than anticipated. At pricing, the company raised 30% more in proceeds than expected.
Immunome plans to list on the Nasdaq under the symbol IMNM. Ladenburg Thalmann and Chardan Capital Markets acted as joint bookrunners on the deal.
